Literature DB >> 15505131

Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction.

Frederick A Spencer1, Gregg C Fonarow, Paul D Frederick, R Scott Wright, Nathan Every, Robert J Goldberg, Joel M Gore, Wei Dong, Richard C Becker, William French.   

Abstract

BACKGROUND: There is increasing interest in the non-lipid-lowering effects of statins and their effect on outcomes in patients with acute coronary syndrome. It has been suggested that withdrawal of statin therapy during an acute coronary syndrome may attenuate any benefits of pretreatment, thereby providing indirect evidence of the importance of their non-lipid-lowering effects.
METHODS: This observational study compared the demographic and clinical characteristics and hospital outcomes in patients with non-ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction 4. Comparison groups consisted of patients previously receiving statins who also received statins within 24 hours of hospital admission (n = 9,001), patients previously using statins in whom therapy was discontinued (n = 4,870), and patients who did not receive statins at any time before or during hospitalization (n = 54,635).
RESULTS: Of 13,871 patients receiving statins before hospital admission, 35.1% had treatment withdrawn during the first 24 hours of hospitalization. These patients had increased hospital morbidity and mortality rates relative to patients in whom therapy was continued, with higher rates of heart failure, ventricular arrhythmias, shock, and death. In multivariate analyses, these patients were at statistically significant increased risk of hospital death compared with those continuing statin therapy and at similar risk compared with those not receiving statins before or during hospitalization.
CONCLUSIONS: Withdrawal of statin therapy in the first 24 hours of hospitalization for non-ST-segment elevation myocardial infarction is associated with worse hospital outcomes. In the absence of data from randomized clinical trials, our findings suggest that statin therapy should be continued during hospitalization for myocardial infarction unless strongly contraindicated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15505131     DOI: 10.1001/archinte.164.19.2162

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  25 in total

1.  A viewpoint on statin effects − benefits and problems.

Authors:  Thomas F Whayne
Journal:  Int J Angiol       Date:  2008

2.  Coronary atherosclerosis, low-density lipoproteins and markers of thrombosis, inflammation and endothelial dysfunction.

Authors:  Thomas F Whayne
Journal:  Int J Angiol       Date:  2007

3.  Time to treatment for acute coronary syndromes: the cost of indecision.

Authors:  Holli A DeVon; Nancy Hogan; Amy L Ochs; Moshe Shapiro
Journal:  J Cardiovasc Nurs       Date:  2010 Mar-Apr       Impact factor: 2.083

4.  Reasons for discontinuation of lipid-lowering medications in patients with chronic kidney disease.

Authors:  Fritha J R Morrison; Huabing Zhang; Stephen Skentzos; Maria Shubina; Rhonda Bentley-Lewis; Alexander Turchin
Journal:  Cardiorenal Med       Date:  2014-11-19       Impact factor: 2.041

Review 5.  Statin rebound or withdrawal syndrome: does it exist?

Authors:  Andres Pineda; Luigi X Cubeddu
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

6.  Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial).

Authors:  Petr Ostadal; David Alan; Jiri Vejvoda; Jiri Kukacka; Milan Macek; Petr Hajek; Martin Mates; Milan Kvapil; Jiri Kettner; Martin Wiendl; Ondrej Aschermann; Josef Slaby; Frantisek Holm; Peter Telekes; David Horak; Peter Blasko; David Zemanek; Josef Veselka; Jana Cepova
Journal:  Trials       Date:  2010-05-25       Impact factor: 2.279

7.  Pleiotropic effects: should statins be considered an essential component in the treatment of dyslipidemia?

Authors:  Maureen E Mays; Carlos A Dujovne
Journal:  Curr Atheroscler Rep       Date:  2008-02       Impact factor: 5.113

Review 8.  Adjunctive interventions in myocardial infarction: the role of statin therapy.

Authors:  Peter H Jones; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2008-04       Impact factor: 5.113

Review 9.  Should a statin be prescribed to every patient with heart failure?

Authors:  Sofia G Tsouli; Evangelos N Liberopoulos; John A Goudevenos; Dimitri P Mikhailidis; Moses S Elisaf
Journal:  Heart Fail Rev       Date:  2007-08-12       Impact factor: 4.214

10.  Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process.

Authors:  Kevin T Bain; Holly M Holmes; Mark H Beers; Vittorio Maio; Steven M Handler; Stephen G Pauker
Journal:  J Am Geriatr Soc       Date:  2008-09-02       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.